

**S6 Table.** Palliative endocrine treatment (yes: n=35, 62.5%, no: n=21, 37.5%)

First line	n=35	Second line	n=8	Third line	n=2
<b>2010-2019</b>	<b>21 (60)</b>	<b>2010-2019</b>	<b>6 (75)</b>	<b>2010-2019</b>	
Letrozole	5 (14.3)	Letrozole	2 (25)	Letrozole+GnRHa	1
Letrozole+GnRHa	1 (2.9)	Letrozole+GnRHa	2 (25)		
Anastrozole	1 (2.9)	Exemestane+everolimus	1 (12.5)		
Exemestane+everolimus	1 (2.9)	Exemestane+GnRHa	1 (12.5)		
Tamoxifen or Toremifene	12 (34.3)				
Tamoxifen+GnRHa	1 (2.9)				
Median PFS	6.67 (0.43-44.63)	Median PFS	3.47 (1.27-11.93)		
<b>2000-2009</b>	<b>11 (31.4)</b>	<b>2000-2009</b>	<b>2 (25)</b>	<b>2000-2009</b>	
Letrozole	4 (11.4)	Anastrozole	1 (12.5)	Exemestane+everolimus	1
Letrozole+GnRHa	1 (2.9)	Tamoxifen or Toremifene	1 (12.5)		
Anastrozole	2 (5.7)				
Tamoxifen or Toremifene	4 (11.4)				
Median PFS	8.20 (1.63-13.17)	Median PFS	3.17 (1.87-4.47)		
<b>Unknown period</b>	<b>3 (8.6)</b>				
Tamoxifen or Toremifene	3 (8.6)				

Values are presented as number (%). GnRHa, gonadotropin-releasing hormone agonist; PFS, progression-free survival.